GENSCRIPT BIO Surges Over 5% as Associate Legend Biotech Reports Narrowed Loss and Strong CARVYKTI® Sales Growth

Stock News05-13

GENSCRIPT BIO (01548) rose more than 5%, with the stock up 5.03% to HK$15.23 at the time of writing, with a turnover of HK$296.96 million. The increase follows a surge of over 10% in the share price of its associate company, Legend Biotech, overnight. Legend Biotech yesterday announced its unaudited financial results and key highlights for the first quarter of 2026. Compared to the first quarter of 2025, net sales of CARVYKTI® in Q1 2026 grew by 62% to approximately $597 million. Within this, net sales in the U.S. market increased by 36%, while net sales in markets outside the U.S. surged by 222%. Additionally, the company's net loss for the three months ended March 31, 2026, narrowed to $54.3 million, compared to a net loss of $101.0 million in the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191336529?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191336529","market":"sg","top_or_hot":-1,"title":"GENSCRIPT BIO Surges Over 5% as Associate Legend Biotech Reports Narrowed Loss and Strong CARVYKTI® Sales Growth","media":"Stock News","content":"<p>GENSCRIPT BIO (01548) rose more than 5%, with the stock up 5.03% to HK$15.23 at the time of writing, with a turnover of HK$296.96 million. The increase follows a surge of over 10% in the share price of its associate company, Legend Biotech, overnight. Legend Biotech yesterday announced its unaudited financial results and key highlights for the first quarter of 2026. Compared to the first quarter of 2025, net sales of CARVYKTI® in Q1 2026 grew by 62% to approximately $597 million. Within this, net sales in the U.S. market increased by 36%, while net sales in markets outside the U.S. surged by 222%. Additionally, the company's net loss for the three months ended March 31, 2026, narrowed to $54.3 million, compared to a net loss of $101.0 million in the same period last year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO Surges Over 5% as Associate Legend Biotech Reports Narrowed Loss and Strong CARVYKTI® Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO Surges Over 5% as Associate Legend Biotech Reports Narrowed Loss and Strong CARVYKTI® Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) rose more than 5%, with the stock up 5.03% to HK$15.23 at the time of writing, with a turnover of HK$296.96 million. The increase follows a surge of over 10% in the share price of its associate company, Legend Biotech, overnight. Legend Biotech yesterday announced its unaudited financial results and key highlights for the first quarter of 2026. Compared to the first quarter of 2025, net sales of CARVYKTI® in Q1 2026 grew by 62% to approximately $597 million. Within this, net sales in the U.S. market increased by 36%, while net sales in markets outside the U.S. surged by 222%. Additionally, the company's net loss for the three months ended March 31, 2026, narrowed to $54.3 million, compared to a net loss of $101.0 million in the same period last year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1191336529","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191336529","pubTimestamp":1778636300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENSCRIPT BIO (01548) rose more than 5%, with the stock up 5.03% to HK$15.23 at the time of writing, with a turnover of HK$296.96 million. The increase follows a surge of over 10% in the share price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1141":"生命科学工具和服务","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1576":"医药外包概念","01548":"金斯瑞生物科技","BK4505":"高瓴资本持仓","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LEGN":"传奇生物","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4588":"碎股","BK4139":"生物科技","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念"},"translate_title":"联想生物科技报告亏损收窄且CARVYKTI强劲，金斯瑞生物股价飙升逾5%®销售增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1,"LEGN":1,"VXUS":1},"content_text":"GENSCRIPT BIO (01548) rose more than 5%, with the stock up 5.03% to HK$15.23 at the time of writing, with a turnover of HK$296.96 million. The increase follows a surge of over 10% in the share price of its associate company, Legend Biotech, overnight. Legend Biotech yesterday announced its unaudited financial results and key highlights for the first quarter of 2026. Compared to the first quarter of 2025, net sales of CARVYKTI® in Q1 2026 grew by 62% to approximately $597 million. Within this, net sales in the U.S. market increased by 36%, while net sales in markets outside the U.S. surged by 222%. Additionally, the company's net loss for the three months ended March 31, 2026, narrowed to $54.3 million, compared to a net loss of $101.0 million in the same period last year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191336529","isCrawlerRequest":true}